Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

Contributed by: PR Newswire

Tags

Keymed-IND

More Like This

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Keymed Biosciences Announces 2023 Annual Results and Business Updates

Keymed Biosciences Announces 2026 H1 Results and Business Updates

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Keymed Biosciences Announces Interim Results for First Half of 2024

Keymed Biosciences Announces 2025 Annual Results and Business Updates